Human Multipotent Stem Cell Proteins Induce Apoptosis in Skin Cancer Cells
- 1 Department of Dermatology, University of California, Mt. Zion Cancer Research Center, San Francisco, United States
- 2 Histogen, Inc., San Diego, United States
- 3 Department of Dermatology, University of California, Mt. Zion Cancer Research Center, San Francisco, United States
- 4 Histogen, Inc., San Diego, United States
- 5 Histogen, Inc., San Diego, United States
Abstract
Unique characteristics in fetal development include scar-less wound healing and the paucity of tumor formation. Recent studies have demonstrated that the embryonic microenvironment can reverse melanoma cells to a benign melanocyte phenotype. We bioengineered embryonic-like compositions and tested the anti-cancer activity of this material on a panel of skin cancer lines. To simulate the embryonic environment, neonatal fibroblasts were grown in hypoxic suspen sion cultures. The cells reverted back into multipotent stem cells as evidenced by the upregulation of SOX2, Oct4, NANOG, and KLF4 genes, and by the expression of stem cell-associated proteins including Nodal, Brachyury, Nestin, and Oct4. Cell Conditioned Media (CCM) and human Extracellular Matrix Proteins (hECM) produced by these cells were tested for their ability to reduce cell viability in skin cancer cell lines. In vitro studies with CCM and hECM show reduction in Squamous Cell Carcinoma (SCC), Basal Cell Carcinoma (BCC) and melanoma cell number through upregulation of caspases and induction of apoptosis. In the chick allantoic membrane assay, melanoma load was re duced by up to 80% with hECM treatment compared to vehicle treated controls (p < 0.05). Similar inhibition was seen with SCC cells. In a xenograft mouse model of subcutaneous melanoma, tumor growth was inhibited by 70 % - 90%. These data suggest that CCM and hECM have anti tumor potential and might offer a new treatment strategy in skin cancer .
- C. T. Mierke, “The Biomechanical Properties of 3D Extracellular Matrices and Embedded Cells Regulate the Invasiveness of Cancer Cells,” Cell Biochemistry and Biophysics, 2011.
- P. M. Kulesa, J. C. Kasemeier-Kulesa, J. M. Teddy, N. V. Margaryan, E. A. Seftor, R. E. B. Seftor and M. J. C. Hendrix, “Reprogramming Metastatic Melanoma Cells to Assume a Neural Crest Cell-Like Phenotype in an Embryonic Microenvironment,” PNAS, Vol. 103, No. 10, 2006, pp. 3752-3753. doi:10.1073/pnas.0506977103
- M. J. C. Hendrix, E. A. Seftor, A. R. Hess and R. E. B. Seftor, “Molecular Plasticity of Human Melanoma Cells,” 2003, pp. 3070-3075.
- T. Mizuno, H. Fukamachi and Y. S. Kim, “Gland Formation of Colon Cancer Cells Combined with Foetal Rat Mesenchymal in Organ Culture: An Ultrastructural Study,” Journal of Cell Science, Vol. 87, No. P5, 1987, pp. 615-621.
- N. Hayashi and G. Cunha, “Mesenchymal-Induced Changes in the Neoplastic Characteristics of the Dunning Prostatic Adenocarcinoma,” Cancer Research, Vol. 51, No. 18, 1991, pp. 4924-4930.
- M. Cooper and H. Pinkus, “Intrauterine Transplantation of Rat Basal Cell Carcinoma as Model for Reconversion of Malignant to Benign Growth,” Cancer Research, Vol. 37, No. 8, 1977, pp. 2544-2552.
- L.-M. Posavit, E. Seftor, R. Seftor and M. Hendrix, “Influence of Microenvironment on Melanoma Cell Fate Determination and Cell Fate,” Cancer Research, Vol. 66, No. 16, 2006, pp. 7833-7836. doi:10.1158/0008-5472.CAN-06-0731
- S. Goldoni, D. G. Seidler, J. Heath, M. Fasson, R. Baffa, M. L. Thakur, R. T. Owens, D. J. McQuilan and R. V. Iozza, “An Antimetastatic Role for Decorin in Breast Cancer,” American Journal of Pathology, Vol. 173, No. 3, 2008, pp. 844-855. doi:10.2353/ajpath.2008.080275
- M. Santra, I. Eichstetter and R. V. Iozza, “An Anti-Oncogenic Role for Decorin: Downregulation of ErbB2 Leads to Growth Suppression and Cytodifferentiation of Mammary Carcinoma Cells, JBC,” 2000.
- J. Muschler, D. Levy and R. Boudreau, “The Role for Dystroglycan in Epithelial Polarization: Loss of Unction in Breast Tumor Cells,” Cancer Research, Vol. 62, No. 23, 2002, pp. 7102-7109
- M. Henry, M. Cohen and K. Campbell, “Reduced Expression of Dystroglycan in Breast and Prostate Cancer,” Human Pathology, Vol. 32, No. 8, 2001, pp. 791-795. doi:10.1053/hupa.2001.26468
- A. Sudhakar, H. Sugimoto, C. Yang, J. Lively, M. Zeisberg and R. Kalluri, “Human Tumstatin and Human Endostatin Exhibit Distinct Antiangiogenic Activities Mediated by Alpha v Beta 3 and Alpha 5 Beta 1 Integrins,” Proceedings of the National Academy of Sciences of the USA, Vol. 100, No. 8, 2003, pp. 4766-4771. doi:10.1073/pnas.0730882100